Search

Your search keyword '"O'Shea, Kelly J"' showing total 30 results
Start Over Author "O'Shea, Kelly J"
30 results on '"O'Shea, Kelly J"'

4. A Systems Map of the Challenges of Climate Communication

Author

Heneghan, Jessie, primary, John, Danielle C., additional, Bartsch, Sarah M., additional, Piltch-Loeb, Rachael, additional, Gilbert, Christine, additional, Kass, Dan, additional, Chin, Kevin L., additional, Dibbs, Alexis, additional, Shah, Tej D., additional, O’Shea, Kelly J., additional, Scannell, Sheryl A., additional, Martinez, Marie F., additional, and Lee, Bruce Y., additional

Published
2024
Full Text
View/download PDF

7. Health and Economic Value of Eliminating Socioeconomic Disparities in US Youth Physical Activity

Author

Powell-Wiley, Tiffany M., primary, Martinez, Marie F., additional, Heneghan, Jessie, additional, Weatherwax, Colleen, additional, Osei Baah, Foster, additional, Velmurugan, Kavya, additional, Chin, Kevin L., additional, Ayers, Colby, additional, Cintron, Manuel A., additional, Ortiz-Whittingham, Lola R., additional, Sandler, Dana, additional, Sharda, Sonal, additional, Whitley, Meredith, additional, Bartsch, Sarah M., additional, O’Shea, Kelly J., additional, Tsintsifas, Alexandra, additional, Dibbs, Alexis, additional, Scannell, Sheryl A., additional, and Lee, Bruce Y., additional

Published
2024
Full Text
View/download PDF

8. What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?

Author

Bartsch, Sarah M, O'Shea, Kelly J, Weatherwax, Colleen, Strych, Ulrich, Velmurugan, Kavya, John, Danielle C, Bottazzi, Maria Elena, Hussein, Mustafa, Martinez, Marie F, Chin, Kevin L, Ciciriello, Allan, Heneghan, Jessie, Dibbs, Alexis, Scannell, Sheryl A, Hotez, Peter J, and Lee, Bruce Y

Subjects
*SARS-CoV-2, *COVID-19, *SARS-CoV-2 Omicron variant, *VACCINE effectiveness, *MONETARY incentives
Abstract

Background With coronavirus disease 2019 (COVID-19) vaccination no longer mandated by many businesses/organizations, it is now up to individuals to decide whether to get any new boosters/updated vaccines going forward. Methods We developed a Markov model representing the potential clinical/economic outcomes from an individual perspective in the United States of getting versus not getting an annual COVID-19 vaccine. Results For an 18–49 year old, getting vaccinated at its current price ($60) can save the individual on average $ 30–$603 if the individual is uninsured and $4–$437 if the individual has private insurance, as long as the starting vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ≥50% and the weekly risk of getting infected is ≥0.2%, corresponding to an individual interacting with 9 other people in a day under Winter 2023–2024 Omicron SARS-CoV-2 variant conditions with an average infection prevalence of 10%. For a 50–64 year old, these cost-savings increase to $111–$1278 and $119–$1706 for someone without and with insurance, respectively. The risk threshold increases to ≥0.4% (interacting with 19 people/day), when the individual has 13.4% preexisting protection against infection (eg, vaccinated 9 months earlier). Conclusions There is both clinical and economic incentive for the individual to continue to get vaccinated against COVID-19 each year. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. The Impact of a Place-Tailored Digital Health App Promoting Exercise Classes on African American Women’s Physical Activity and Obesity: Simulation Study

Author

Powell-Wiley, Tiffany M, primary, Martinez, Marie F, additional, Tamura, Kosuke, additional, Neally, Sam J, additional, O'Shea, Kelly J, additional, Curlin, Kaveri, additional, Albarracin, Yardley, additional, Vijayakumar, Nithya P, additional, Morgan, Matthew, additional, Ortiz-Chaparro, Erika, additional, Bartsch, Sarah M, additional, Osei Baah, Foster, additional, Wedlock, Patrick T, additional, Ortiz-Whittingham, Lola R, additional, Scannell, Sheryl, additional, Potharaju, Kameswari A, additional, Randall, Samuel, additional, Solano Gonzales, Mario, additional, Domino, Molly, additional, Ranganath, Kushi, additional, Hertenstein, Daniel, additional, Syed, Rafay, additional, Weatherwax, Colleen, additional, and Lee, Bruce Y, additional

Published
2022
Full Text
View/download PDF

11. The potential epidemiologic, clinical, and economic impact of requiring schools to offer Physical Education (PE) classes in Mexico City

Author

Ferguson, Marie C., primary, Bartsch, Sarah M., additional, O’Shea, Kelly J., additional, Thomas, Diana M., additional, Moran, Timothy H., additional, Solano Gonzales, Mario, additional, Wedlock, Patrick T., additional, Nyathi, Sindiso, additional, Morgan, Matthew, additional, Chin, Kevin L., additional, Scannell, Sheryl A., additional, Hertenstein, Daniel L., additional, Domino, Molly, additional, Ranganath, Kushi, additional, Adam, Atif, additional, Tomaino Fraser, Katherine, additional, Fraser, Adam, additional, and Lee, Bruce Y., additional

Published
2022
Full Text
View/download PDF

16. The impact of reducing the frequency of night feeding on infant BMI

Author

O’Shea, Kelly J., primary, Ferguson, Marie C., additional, Esposito, Layla, additional, Hammer, Lawrence D., additional, Avelis, Cameron, additional, Hertenstein, Daniel, additional, Gonzales, Mario Solano, additional, Bartsch, Sarah M., additional, Wedlock, Patrick T., additional, Siegmund, Sheryl S., additional, and Lee, Bruce Y., additional

Published
2021
Full Text
View/download PDF

18. Estimated number of N95 respirators needed for healthcare workers in acute-care hospitals during the coronavirus disease 2019 (COVID-19) pandemic

Author

Wedlock, Patrick T., primary, O’Shea, Kelly J., additional, Conte, Madellena, additional, Bartsch, Sarah M., additional, Randall, Samuel L., additional, Ferguson, Marie C., additional, Cox, Sarah N., additional, Siegmund, Sheryl S., additional, Kulkarni, Sarah, additional, Nash, Denis, additional, Lin, Michael Y., additional, and Lee, Bruce Y., additional

Published
2021
Full Text
View/download PDF

20. Modeling Nursing Home Harms From COVID-19 Staff Furlough Policies.

Author

Bartsch, Sarah M., Weatherwax, Colleen, Leff, Bruce, Wasserman, Michael R., Singh, Raveena D., Velmurugan, Kavya, John, Danielle C., Chin, Kevin L., O'Shea, Kelly J., Gussin, Gabrielle M., Martinez, Marie F., Heneghan, Jessie L., Scannell, Sheryl A., Shah, Tej D., Huang, Susan S., and Lee, Bruce Y.

Published
2024
Full Text
View/download PDF

21. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention

Author

Bartsch, Sarah M., primary, O'Shea, Kelly J., additional, Ferguson, Marie C., additional, Bottazzi, Maria Elena, additional, Wedlock, Patrick T., additional, Strych, Ulrich, additional, McKinnell, James A., additional, Siegmund, Sheryl S., additional, Cox, Sarah N., additional, Hotez, Peter J., additional, and Lee, Bruce Y., additional

Published
2020
Full Text
View/download PDF

26. Using Simulation Modeling to Guide the Design of the Girl Scouts Fierce & Fit Program

Author

Ferguson, Marie C., primary, Morgan, Matthew J., additional, O’Shea, Kelly J., additional, Winch, Lucas, additional, Siegmund, Sheryl S., additional, Solano Gonzales, Mario, additional, Randall, Samuel, additional, Hertenstein, Daniel L., additional, Montague, Valerie, additional, Woodberry, Ayanna, additional, Cassatt, Trish, additional, and Lee, Bruce Y., additional

Published
2020
Full Text
View/download PDF

28. Lives and Costs Saved by Expanding and Expediting COVID-19 Vaccination.

Author

Bartsch, Sarah M, Wedlock, Patrick T, O'Shea, Kelly J, Cox, Sarah N, Strych, Ulrich, Nuzzo, Jennifer B, Ferguson, Marie C, Bottazzi, Maria Elena, Siegmund, Sheryl S, Hotez, Peter J, and Lee, Bruce Y

Subjects
COVID-19, VACCINE effectiveness, VACCINE hesitancy, VACCINATION, MEDICAL care costs
Abstract

Background: With multiple COVID-19 vaccines available, understanding the epidemiologic, clinical, and economic value of increasing coverage levels and expediting vaccination is important.Methods: We developed a computational model (transmission and age-stratified clinical and economics outcome model) representing the US population, COVID-19 coronavirus spread (02/2020-12/2022), and vaccination to determine the impact of increasing coverage and expediting time to achieve coverage.Results: When achieving a given vaccination coverage in 270 days (70% vaccine efficacy), every 1% increase in coverage can avert an average of 876,800 (217,000-2,398,000) cases, varying with the number of people already vaccinated. For example, each 1% increase between 40%-50% coverage can prevent 1.5million cases, 56,240 hospitalizations, 6,660 deaths, gain 77,590 QALYs, save $602.8 million in direct medical costs and $1.3 billion in productivity losses . Expediting to 180 days could save an additional 5.8 million cases, 215,790 hospitalizations, 26,370 deaths, 206,520 QALYs, $3.5 billion in direct medical costs, and $4.3 billion in productivity losses.Conclusion: Our study quantifies the potential value of decreasing vaccine hesitancy and increasing vaccination coverage and how this value may decrease with time it takes to achieve coverage, emphasizing the need to reach high coverage levels as soon as possible, especially before the Fall/Winter. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. How Efficacious Must a COVID-19 Coronavirus Vaccine be to Prevent or Stop an Epidemic by Itself.

Author

Bartsch SM, O'Shea KJ, Ferguson MC, Bottazzi ME, Cox SN, Strych U, McKinnell JA, Wedlock PT, Siegmund SS, Hotez PJ, and Lee BY

Abstract

Background: Given the continuing coronavirus disease 2019 (COVID-19) pandemic and much of the U.S. implementing social distancing due to the lack of alternatives, there has been a push to develop a vaccine to eliminate the need for social distancing., Methods: In 2020, we developed a computational model of the U.S. simulating the spread of COVID-19 coronavirus and vaccination., Results: Simulation experiments revealed that when vaccine efficacy exceeded 70%, coverage exceeded 60%, and vaccination occurred on day 1, the attack rate dropped to 22% with daily cases not exceeding 3.2 million (reproductive rate, R0, 2.5). When R0 was 3.5, the attack rate dropped to 41% with daily cases not exceeding 14.4 million. Increasing coverage to 75% when vaccination occurred by day 90 resulted in 5% attack rate and daily cases not exceeding 258,029when R0 was 2.5 and a 26% attack rate and maximum daily cases of 22.6 million when R0 was 3.5. When vaccination did not occur until day 180, coverage (i.e., those vaccinated plus those otherwise immune) had to reach 100%. A vaccine with an efficacy between 40% and 70% could still obviate the need for other measures under certain circumstances such as much higher, and in some cases, potentially unachievable, vaccination coverages., Conclusion: Our study found that to either prevent or largely extinguish an epidemic without any other measures (e.g., social distancing), the vaccine has to have an efficacy of at least 70%.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results